Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286875 | 0.83 | ADRA2A (0.49) | POLBMAPTPKMCA2CYP3A4 | |
| SCHEMBL3290960 | 0.81 | KMT2A (0.58) | POLBMAPTGAAALDH1A1LMNA | |
| SCHEMBL23417965 | 0.80 | KDM4E (0.52) | MAPTPKMCA2KDM4EGLA | |
| SCHEMBL2489186 | 0.76 | SMN1; SMN2 (0.53) | MAPTKDM1AMAOAKDM4EHSD17B10 | |
| SCHEMBL823757 | 0.75 | LMNA (0.52) | POLBMAPTPKMMAOAKDM4E | |
| SCHEMBL31621879 | 0.75 | LMNA (0.52) | POLBMAPTPKMMAOAKDM4E | |
| SCHEMBL15754401 | 0.74 | KDM4E (0.70) | POLBMAPTCA2KDM4EHSD17B10 | |
| SCHEMBL6364376 | 0.74 | MAPT (0.56) | POLBMAPTPKMCA2KDM4E | |
| SCHEMBL27656526 | 0.72 | ACHE (0.43) | — | |
| SCHEMBL3287743 | 0.72 | NPC1 (0.52) | PKMKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| EP-1112252-A4 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6492351-B1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-12-10 | — | — | US | disclosed |
| US-6486165-B2 | TREATING WITH AGONISTS AT KAPPA OPIOID RECEPTORS SUCH AS METHYL-4-(2-GLYCYL-4-(TRIFLUOROMETHYLPHENYL)ACETYL)-3-(R,S)-((1 -PYRROLIDINYL)-METHYL)-1-PIPERAZINECARBOXYLATE | ADOLOR CORPORATION | 2002-11-26 | — | — | US | disclosed |
| US-6476063-B2 | DEVOID OF CENTRAL NERVOUS SYSTEM EFFECTS; TOPICAL AND SYSTEMIC ADMINISTRATION; ANTIPRURITIC AGEENTS; ANALGESICS 1-ARYLMETHYLCARBONYL-2-PYRROLIDIN-1-YL-PIPERAZINES | ADOLOR CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6391910-B1 | OPIOID ANTAGONIST; ANALGESIC | ADOLOR CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6303611-B1 | FOR THERAPY OF HYPERALGESIS | ADOLOR CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-1112252-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | Adolor Corporation (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6239154-B1 | ARYLACETAMIDES, AGONISTS AT KAPPA OPIOID RECEPTORS. | ADOLOR CORPORATION | 2001-05-29 | — | — | US | disclosed |
| US-6057323-A | PIPERAZINE DERIVATIVES | ADOLOR CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| WO-2000014065-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORPORATION (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | BRAF 3996/4885POLB 2725/4885MAPT 3158/4885 |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | BRAF 4613/4885POLB 1884/4885MAPT 2990/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | BRAF 4644/4885POLB 1997/4885MAPT 2935/4885 |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | BRAF 3996/4885POLB 2725/4885MAPT 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.